You are here

Research & Development

As an emerging player in next-generation IO science, we recognize the urgency of our mission to help patients in need of anti-cancer alternatives. As of April 2017, we have 11 compounds in ongoing IO clinical trials. And that’s just the beginning. Going forward, we are committed to bringing novel IO agents into the clinic.

Explore the assets in our IO product pipeline


BEYOND SINGLE AGENTS: THE POTENTIAL TO HELP MORE PATIENTS THROUGH IO COMBINATIONS

Currently approved cancer immunotherapies—specifically, the checkpoint inhibitors PD-1, PD-L1, and CTLA-4*—have shown promising results. These agents work for many but not all patients and work differently in different tumor types.1-3 However, in patients who do respond, response is generally durable and long-lasting.1

In patients who do not respond to checkpoint inhibition with single agents, IO combinations may provide an option.

*Blocking the checkpoint proteins PD-1, PD-L1, and CTLA-4 helps sustain the immune response.
Although higher tumor response rates have been reported in some studies, they have been seen mostly in select groups of patients.1

PD-1=programmed death 1; PD-L1=programmed death ligand 1; CTLA-4=cytotoxic T-lymphocyte–associated protein-4.

1NIH-National Cancer Institute. Checking in on checkpoint inhibitors. Cancer currents blog. December 18, 2015. https://www.cancer.gov/news-events/cancer-currents-blog/2015/gulley-chec.... Accessed November 3, 2016.
2Richter V. Clinical trials show success for new cancer treatment. Cosmos. June 13, 2016. https://cosmosmagazine.com/biology/clinical-trial-show-success-for-new-c.... Accessed November 3, 2016.
3Gorman C. Cancer immunotherapy: The cutting edge gets sharper. Scientific American. October 1, 2015. https://www.scientificamerican.com/article/cancer-immunotherapy-the-cutt.... Accessed November 4, 2016.

DIVERSE IO PATHWAYS, EMERGING TECHNOLOGIES AND APPROACHES

At Pfizer Oncology, we understand the tremendous need for better, more targeted cancer treatments. That’s why we are relentlessly exploring the underlying mechanisms of the immune system, the microenvironment in which cancer cells grow, and the multiple pathways that contribute to the growth and spread of tumors. We’re employing both traditional and cutting-edge technologies to target these pathways.

Efficacy and safety of agents targeting these pathways are currently under investigation. Regulatory approval of any of these agents is dependent upon completion of the study programs and regulatory review by authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of April 2017.

Efficacy and safety of agents targeting these pathways are currently under investigation. Regulatory approval of any of these agents is dependent upon completion of the study programs and regulatory review by authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of April 2017.

PD-1

PD-L1

CTLA-4

4-1BB

OX40

IDO1

MCSF

BCMA

Monoclonal antibodies

P-cadherin (bispecific)

CAR-T

Oncolytic virus

VBIR

CXCR4


OUR PIPELINE

Our strategy is built on the depth and breadth of our portfolio:

  • We have robust capabilities in developing traditional compounds, including small molecules and monoclonal antibodies
  • We focus on the novel use of cutting-edge technologies in the development of CAR-T cells, IO vaccines, oncolytic viruses, and bispecific antibodies
  • We have a broad array of compounds at various stages of clinical development Explore the IO assets in our product pipeline

 

Explore the IO assets in our product pipeline


 

Find out about Pfizer IO clinical trials

Find Pfizer IO clinical trials that are enrolling patients


OUR R&D PROGRAM

We are making significant contributions to the science of IO with research and development efforts that span diverse modalities and mechanisms of action.

We see our R&D program as being in a strong position to help advance IO science, because we are the company with the most advanced IO pipeline that includes a PDL-1, 4-1BB, and OX40 agent. As of April 2017, we have 11 compounds in ongoing IO clinical trials. We are committed to going wherever the science leads.

In addition to our IO assets, we are also exploring a broad range of antibody-drug conjugates (ADCs) and small molecules in various combinations.

Learn more about our IO clinical trials in the National Institutes of Health registry


OVERVIEW OF OUR IO CLINICAL TRIALS PROGRAM*

Click below to see all of the IO combinations we’re investigating.

PD-L1 Monoclonal Antibodies BackBone

Combinations with Pfizer IO agents

Combinations with Pfizer targeted agents

Combinations developed through external collaborations

⚪ Ongoing studies
∇  Planned studies

*Efficacy and safety of agents targeting these pathways are currently under investigation. Regulatory approval of any of these agents is dependent upon completion of the study programs and regulatory review by authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of April 2017.


OUR GLOBAL FOCUS


RESEARCH PERSPECTIVES

Meet the hard-working scientists behind Pfizer’s next generation of investigational IO molecules and find out what they’re working on.

The people behind the science

Pfizer Oncology researchers discuss their work.

 

Pfizer Talks Possibilities

Taking the temperature of immuno-oncology.

 

Barbra Sasu on re-engineering T-cells to fight cancer

Vice President, CAR-T

 

Jean-Francois Martini on harnessing the immune system to fight tumors

Senior Director, Early Development, Translational and Immuno-Oncology

We’re attempting to speed our ability to bring breakthroughs to patients with cancer by bringing forward various potential opportunities and IO combinations very rapidly.

- Steffan Ho, MD, PhD Executive Director, Head of Translational Oncology, Pfizer Global Product Development